Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
30 oct. 2024 16h30 HE
|
Cardiff Oncology, Inc.
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC - - Post hoc analysis...
Liteye C-AUDS Chosen to Defend Critical Infrastructure by the US Government
16 juil. 2020 07h27 HE
|
Liteye Systems, Inc.
Centennial, Colorado, July 16, 2020 (GLOBE NEWSWIRE) -- Centennial, Colo. (July 15, 2020) — Liteye Systems, Inc., is pleased to announce the selection of its Containerized Anti-UAS Defense Systems...